SAB BIO Announces Third Quarter 2024 Financial Results and …

Nov 6, 2024 · Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data …

CouponFollow Extension

$10
OFF

SABSW - SAB BIO Announces Third Quarter 2024 Financial...

1 week from now

SAB BIO reported a net loss of $10.3 million for the third quarter, translating to an earnings per share (EPS) loss of $1.12, widening from a net loss of $5.1 million in Q3 2023. Despite the …

marketwirenews.com

$167
OFF

Boundless Bio Reports Third Quarter 2024 Financial Results And …

1 week from now

Nov 7, 2024 · Third Quarter 2024 Financial Results. Cash Position: Cash, cash equivalents, and short-term investments totaled $167.1 million as of September 30, 2024. R&D Expenses: …

boundlessbio.com

$2
OFF

Chemomab Therapeutics Announces Third Quarter 2024 Financial …

1 week from now

1 day ago · Research and Development (R&D) Expenses: R&D expenses were $2.8 million for the third quarter of 2024, compared to $3.4 million for the third quarter of 2023. The decrease …

biospace.com

$10
OFF

PacBio Announces Third Quarter 2024 Financial Results

1 week from now

Nov 7, 2024 · Gross profit for the third quarter of 2024 was $10.0 million, which reflected a $3.2 million expense related to the amortization of acquired intangible assets, compared with $17.9 …

pacb.com

$7
OFF

Clearside Biomedical Announces Third Quarter 2024 Financial …

1 week from now

Sep 30, 2024 · Net loss for the third quarter of 2024 was $7.7 million, or $0.10 per share of common stock, compared to net loss of $9.3 million, or $0.15 per share of common stock, for …

clearsidebio.com

$17
OFF

Spero Therapeutics Announces Third Quarter 2024 Operating …

1 week from now

Spero reported a net loss of $17.1 million, or ($0.32) per share of common stock, basic and diluted, for the third quarter ended September 30, 2024, compared with a net loss of $3.2 …

nasdaq.com

$10
OFF

Senti Bio Announces Third Quarter 2024 Results And Recent …

1 week from now

2 days ago · SELECTED THIRD QUARTER 2024 FINANCIAL RESULTS. Cash and Cash Equivalents: As of September 30, 2024, Senti Bio held cash and cash equivalents of $10.5 …

businessinsider.com

$26
OFF

Cabaletta Bio Reports Third Quarter 2024 Financial Results And …

1 week from now

2 days ago · Third Quarter 2024 Financial Results Research and development expenses were $26.3 million for the three months ended September 30, 2024, compared to $13.8 million for …

businessinsider.com

12%
OFF

CASI Pharmaceuticals Announces Third Quarter 2024 Business And ...

1 week from now

1 day ago · Total revenue was $7.8 million for the three months ended September 30, 2024, representing a 12% decrease compared to the same period in 2023 and a 96% increase …

biospace.com

FAQs about SAB BIO Announces Third Quarter 2024 Financial Results and … Coupon?

What does SAB bio stand for?

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymoc... ...

Will sab-142 perform a topline Phase 1 data readout?

SAB-142 remains on track for a topline Phase 1 data readout by the end of the year. Q3 2024 Financial Updates Financial Guidance: Based on its current operating plans, if the Company receives funds upon the exercise of all outstanding Tranche B warrants, SAB would have cash sufficient to fund its operations into 2026. ...

Does SAB 142 have a clinical trial progress update?

Corporate Updates SAB provided a clinical trial progress update on September 9, 2024 at the European Association for the Study of Diabetes Annual Meeting. The update confirmed that SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers. ...

Is sab-142 a fully-human anti-thymocyte immunoglobulin?

SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human a... First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG) ...

Is SAB based on current expectations?

These statements are based on the current expectations of SAB and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. ...

What were the financial results of 3rd quarter 2024?

Third Quarter 2024 Financial Results Research and development expenses were $26.3 million for the three months ended September 30, 2024, compared to $13.8 million for the same period in 2023. General and administrative expenses were $6.8 million for the three months ended September 30, 2024, compared to $4.9 million for the same period in 2023. ...